ADS Insights
Long/short equity, deep value, value, special situations

CONMED: Aggressive Accounting And Increased Debt Mask Its Problems

CONMED (NASDAQ:CNMD) shot up over 7% on April 15 after the company announced that it was up for sale. The company competes with other medical device makers such as Stryker (NYSE:SYK) and Covidien (COV). Those two companies and other larger device manufacturers could be possible acquirers of CONMED. However, the company's market valuation is already lofty for a deteriorating business with diminishing cash flow from operations - although its cash flow statement shows different. Further, the company's earnings and operating metrics have benefitted from the accounting treatment of its pension obligations and distribution agreement. The accounting cannot hide the economics forever; therefore, the clock is ticking on CONMED and its stock has little upside with tremendous

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details